Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
66.00    -0.50 (-0.75%)
Bid:
65.00
Ask:
67.00
Spread: 2.00 (3.077%)
Market Cap: £80.07m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

Director/PDMR Shareholding

Today 15:03

RNS Number : 4429K
Venture Life Group PLC
30 June 2026
 

30 June 2026

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Company")

Director/PDMR Shareholding

Venture Life (AIM: VLG), a recognised leader in proactive longevity, health innovation and global commercialisation within the global consumer healthcare sector, announces that Paul McGreevy, Non-Executive Chairman, has today purchased 93,887 ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") at a volume-weighted average price of 63.9 pence per Ordinary Share.

Following the purchase, Mr McGreevy beneficially holds 1,145,985 Ordinary Shares representing approximately 0.89 per cent. of the Company's issued share capital.

 

For further information, please contact:

 

Venture Life Group PLC

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cavendish Capital Markets Limited (Nomad and Broker)

 

+44 (0) 20 7720 0500

Stephen Keys / George Lawson (Corporate Finance)

Michael Johnson (Sales)

 

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK, Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

 

The Company makes the following disclosure in accordance with article 19(3) of the Market Abuse Regulation:

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Paul McGreevy

2

 

Reason for the notification

 

a)

 

Position/status

 

Non-Executive Chairman

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Venture Life Group plc

b)

 

LEI

 

213800S8CZUPLAB2KC70

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

 

Identification code

 

Ordinary Shares of 0.3p each in Venture Life Group plc

 

 

 

GB00BFPM8908

b)

 

Nature of the transaction

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price

Volume

63.875 pence

31,297

63.875 pence

31,297

63.850 pence

15,650

63.880 pence

15,643

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

93,887 Ordinary Shares purchased at a volume-weighted average price of 63.9 pence.

 

 

e)

 

Date of the transaction

 

30 June 2026

f)

 

Place of the transaction

 

London Stock Exchange

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFISRLIIVIR
Date   Source Headline
11th Dec 20257:00 amRNSTransaction in Own Shares
10th Dec 20257:00 amRNSTransaction in Own Shares
9th Dec 20257:00 amRNSSale of Non-Core Products
8th Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20257:00 amRNSTransaction in Own Shares
1st Dec 20254:30 pmRNSTotal Voting Rights
1st Dec 20257:00 amRNSTransaction in Own Shares
28th Nov 20257:00 amRNSTransaction in Own Shares
25th Nov 20257:00 amRNSTransaction in Own Shares
21st Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20257:00 amRNSTransaction in Own Shares
3rd Oct 20254:40 pmRNSDirector/PDMR Shareholding
30th Sep 20257:01 amRNSShare Buyback Programme
30th Sep 20257:00 amRNSInterim Results
29th Sep 202512:19 pmRNSInvestor Presentation via Investor Meet Company
24th Sep 20252:38 pmRNSChange of Accounting Reference Date
8th Sep 20257:00 amRNSDirectorate Change
19th Aug 20252:04 pmRNSHolding(s) in Company
5th Aug 20253:43 pmRNSResult of General Meeting
25th Jul 20257:05 amRNSGrant of Share Options
25th Jul 20257:00 amRNSCompletion of Divestment & Trading Update
7th Jul 20254:21 pmRNSDirector/PDMR Shareholding
3rd Jul 20257:00 amRNSDirector Dealings
2nd Jul 20257:00 amRNSNotice of General Meeting & Investor Presentation
1st Jul 20254:08 pmRNSHolding(s) in Company
30th Jun 20253:15 pmRNSResult of AGM
30th Jun 20253:13 pmRNSFinal Results for year ended 31 December 2024
5th Jun 20252:19 pmRNSNotice of Annual General Meeting
19th May 20257:01 amRNSDirector Dealings
19th May 20257:00 amRNSBoard Update
12th May 20258:49 amRNSReplacement: Cash sale of CDMO operations
12th May 20257:00 amRNSCash sale of CDMO operations
28th Apr 202510:50 amRNSHolding(s) in Company
8th Apr 20254:53 pmRNSHolding(s) in Company
20th Feb 20251:14 pmRNSHolding(s) in Company
18th Feb 202510:02 amRNSHolding(s) in Company
4th Feb 20257:01 amRNSBoard Changes
4th Feb 20257:00 amRNSTrading Statement
21st Jan 20258:15 amRNSExercise of Share Options & Total Voting Rights
20th Jan 202511:49 amRNSHolding(s) in Company
19th Dec 202411:48 amRNSHolding(s) in Company
4th Nov 20243:44 pmRNSHolding(s) in Company
30th Oct 202412:01 pmRNSDirector/PDMR Shareholding
30th Oct 202410:58 amRNSDirector/PDMR Shareholding
30th Oct 20247:00 amRNSAcquisition of Health & Her Limited
1st Oct 202412:47 pmRNSHolding(s) in Company
30th Sep 20247:00 amRNSInterim Results
26th Sep 20247:00 amRNSInvestor Presentation via Investor Meet Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.